All In Biotech

Drug Trial Radar · NCT06305234

A Long Term, Post-marketing Study of Immune Response in Patients Receiving Palynziq Treatment for PKU (PALisade)

A Multi-Center, Prospective, Longitudinal, Study Evaluating Immunologic, Inflammatory, and Laboratory Parameters Associated With Long-Term Palynziq® (Pegvaliase) Treatment in Subjects With Phenylketonuria (PKU) in the United States

Last checked: Nov 20, 2026Latest source record: Mar 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

200

Planned (sponsor's estimate)

Start

Jan 20, 2024

Primary completion

Nov 18, 2033

Study completion Nov 18, 2033

Sponsor

Lead sponsor
BioMarin PharmaceuticalBioMarin (BMRN)
Sponsor type
Industry
First posted
Mar 12, 2024

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
Yes
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a 10-year multi-center, prospective, longitudinal, single arm study evaluating immunologic, inflammatory and laboratory parameters associated with long-term Palynziq treatment in subjects with phenylketonuria (PKU) in the United States (US). Subjects in the US for whom a clinical decision has been made that they will receive pegvaliase to treat their PKU within 30 days following the date of enrollment in Study 165-501 (incident-users) or who have previously started treatment with pegvaliase at the date of enrollment in Study 165-501 (prevalent-users) are eligible for participation in Study 165-503.

Conditions

  • Phenylketonuria (PKU)

Interventions

  • PegvaliaseDrug

    Must be enrolled in the 165-501 PALace study. Subjects currently receiving or who plan to receive pegvaliase treatment within 30 days after the date of enrollment in the 165-501 study, including subjects who previously received pegvaliase as part of the clinical development program and have completed study participation

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To evaluate immunologic and inflammatory responses associated with occurrences ofTime frame: A maximum of 10 years treatment duration.

Locations

11 sites in 1 country. Site status is shown where the registry gives one.

  • University of Colorado

    Aurora, Colorado · Recruiting

  • Emory University

    Atlanta, Georgia · Recruiting

  • Northwestern University

    Chicago, Illinois · Recruiting

  • Riley Children's Hospital/ Indiana University Health

    Indianapolis, Indiana · Recruiting

  • Tulane University School of Medicine

    New Orleans, Louisiana · Recruiting

  • Boston Children's Hospital

    Boston, Massachusetts · Recruiting

  • Oregon Health & Science University

    Portland, Oregon · Recruiting

  • University of Pittsburgh Medical Center

    Pittsburgh, Pennsylvania · Recruiting

  • Vanderbilt University Medical School

    Nashville, Tennessee · Recruiting

  • UT Southwestern Medical Center

    Dallas, Texas · Recruiting

  • Children's Wisconsin/Medical College of Wisconsin

    Milwaukee, Wisconsin · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.